GLP-1-analogues and DPP-4-inhibitors are well-established treatments in type 2 diabetes and recently two major studies of GLP-1-analogues have shown, in addition to lowering blood glucose, a reduced risk of cardiovascular disease29,30 and mortality30. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.